Maynard Um
-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
-
-
-
-
-
-
-
Abbvie (ABBV) PT Raised to $273 at Canaccord
-
-
-
-
-
-
-
AbbVie presents nine-year venetoclax trial results at EHA congress
-
-
-
-
-
-
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
-
-
-
-
-
-
EvolveImmune receives $18 million milestone payment from ABBV partnership
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on Abbvie (ABBV)
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Abbvie (ABBV): "competitive across the amylin class"
-
416,790 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

